Biolinerx Financials
Biolinerx (BLRX) reported $1.2M in revenue for fiscal year 2025, down 95.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioLineRx still operates as a cash-funded development business, with episodic revenue not yet carrying the cost base.
The drop from$28.9M of FY2024 revenue to$1.2M in FY2025 shows sales are still episodic rather than the stable engine funding the company. Even after that swing, operating cash flow stayed negative at-$8.1M and year-end cash was only$3.3M , so the business still relies more on external funding than on self-financing.
What improved in FY2025 was the accounting loss profile: net loss narrowed to
The balance sheet looks less burdened than it did in FY2023, with total liabilities down to
Financial Health Signals
Biolinerx does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Biolinerx passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Biolinerx reported a net loss of $2.0M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Biolinerx generated $1.2M in revenue in fiscal year 2025. This represents a decrease of 95.9% from the prior year.
Biolinerx reported -$2.0M in net income in fiscal year 2025. This represents an increase of 78.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Biolinerx recorded an outflow of $8.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 81.6% from the prior year.
Biolinerx held $3.3M in cash against $977K in long-term debt as of fiscal year 2025, with $12.1M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Biolinerx's ROE was -8.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 59.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Biolinerx invested $25K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BLRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $304K | N/A | $5.4M | N/A | $0 | N/A | N/A |
| Net Income | N/A | -$3.9M | N/A | $484K | N/A | -$18.5M | N/A | -$7.4M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, EPS (Diluted).
BLRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.9M-5.5% | $43.3M+11.2% | $38.9M-39.8% | $64.6M+1.0% | $63.9M+8.5% | $58.9M-22.8% | $76.4M+12.6% | $67.8M |
| Current Assets | $23.7M-25.7% | $31.9M+17.6% | $27.1M-44.8% | $49.1M+4.1% | $47.2M+36.0% | $34.7M-33.3% | $52.0M+17.9% | $44.1M |
| Cash & Equivalents | $3.3M-54.8% | $7.2M-31.1% | $10.4M+8.4% | $9.6M+126.2% | $4.3M-57.9% | $10.1M-4.6% | $10.6M-24.4% | $14.0M |
| Inventory | $2.1M-24.6% | $2.9M-9.4% | $3.1M-13.5% | $3.6M+86.1% | $2.0M | N/A | $0 | N/A |
| Total Liabilities | $17.6M-24.3% | $23.2M-8.8% | $25.4M-49.7% | $50.6M-0.2% | $50.7M+33.8% | $37.9M+48.3% | $25.5M+126.6% | $11.3M |
| Current Liabilities | $12.1M-21.7% | $15.5M+0.5% | $15.4M-49.5% | $30.5M-28.7% | $42.8M+243.8% | $12.4M+16.5% | $10.7M+10.9% | $9.6M |
| Long-Term Debt | $977K-2.1% | $998K-7.7% | $1.1M-17.4% | $1.3M+1.5% | $1.3M-18.8% | $1.6M-8.1% | $1.7M+19.1% | $1.5M |
| Total Equity | $23.3M+16.3% | $20.1M+49.1% | $13.5M-3.1% | $13.9M+5.1% | $13.2M-37.2% | $21.1M-58.6% | $50.8M-10.1% | $56.6M |
| Retained Earnings | -$401.0M-0.6% | -$398.6M+0.3% | -$399.8M-2.3% | -$390.8M-0.1% | -$390.6M-8.3% | -$360.7M-9.3% | -$330.0M-4.0% | -$317.4M |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
BLRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
BLRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Net Margin | N/A | -1296.0% | N/A | 9.0% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -19.6% | N/A | 3.5% | N/A | -88.1% | N/A | -13.2% |
| Return on Assets | N/A | -9.1% | N/A | 0.8% | N/A | -31.5% | N/A | -11.0% |
| Current Ratio | 1.95-0.1x | 2.06+0.3x | 1.76+0.2x | 1.61+0.5x | 1.10-1.7x | 2.79-2.1x | 4.87+0.3x | 4.58 |
| Debt-to-Equity | 0.040.0x | 0.050.0x | 0.080.0x | 0.090.0x | 0.100.0x | 0.080.0x | 0.030.0x | 0.03 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Biolinerx Ranks
Frequently Asked Questions
What is Biolinerx's annual revenue?
Biolinerx (BLRX) reported $1.2M in total revenue for fiscal year 2025. This represents a -95.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biolinerx's revenue growing?
Biolinerx (BLRX) revenue declined by 95.9% year-over-year, from $28.9M to $1.2M in fiscal year 2025.
Is Biolinerx profitable?
No, Biolinerx (BLRX) reported a net income of -$2.0M in fiscal year 2025.
How much debt does Biolinerx have?
As of fiscal year 2025, Biolinerx (BLRX) had $3.3M in cash and equivalents against $977K in long-term debt.
What is Biolinerx's return on equity (ROE)?
Biolinerx (BLRX) has a return on equity of -8.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biolinerx's free cash flow?
Biolinerx (BLRX) recorded an outflow of $8.1M in free cash flow during fiscal year 2025. This represents a 81.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biolinerx's operating cash flow?
Biolinerx (BLRX) recorded an outflow of $8.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biolinerx's total assets?
Biolinerx (BLRX) had $40.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biolinerx's capital expenditures?
Biolinerx (BLRX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Biolinerx's current ratio?
Biolinerx (BLRX) had a current ratio of 1.95 as of fiscal year 2025, which is generally considered healthy.
What is Biolinerx's debt-to-equity ratio?
Biolinerx (BLRX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biolinerx's return on assets (ROA)?
Biolinerx (BLRX) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biolinerx's Piotroski F-Score?
Biolinerx (BLRX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biolinerx's earnings high quality?
Biolinerx (BLRX) reported a net loss of $2.0M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.